Critical appraisal of the SHARP trial: the results may be dull.


PURPOSE The goal of this commentary was to provide a critical analysis of the SHARP (Study of Heart and Renal Protection) trial. Published in 2011, this study has been used by clinicians to justify the prescribing of statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) ±ezetimibe in patients with chronic kidney disease. METHODS We… (More)
DOI: 10.1016/j.clinthera.2014.10.008


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.